First Hawaiian Bank Has $5.55 Million Position in Sanofi (NASDAQ:SNY)

First Hawaiian Bank grew its position in Sanofi (NASDAQ:SNY) by 1.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 115,024 shares of the company’s stock after purchasing an additional 1,554 shares during the period. First Hawaiian Bank’s holdings in Sanofi were worth $5,548,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Barrow Hanley Mewhinney & Strauss LLC raised its holdings in shares of Sanofi by 113.8% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after acquiring an additional 3,164,092 shares during the period. Magnetar Financial LLC raised its stake in shares of Sanofi by 1,153.1% in the 2nd quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock valued at $121,605,000 after purchasing an additional 2,306,286 shares during the period. Jennison Associates LLC lifted its holdings in shares of Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock valued at $109,753,000 after purchasing an additional 1,720,972 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in shares of Sanofi by 28,890.2% during the third quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock worth $82,366,000 after buying an additional 1,424,289 shares during the period. Finally, Federated Hermes Inc. grew its holdings in shares of Sanofi by 26.5% during the second quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock worth $155,950,000 after buying an additional 673,172 shares in the last quarter. 14.04% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on the company. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Citigroup raised Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Sanofi presently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Price Performance

NASDAQ:SNY traded down $0.64 during mid-day trading on Wednesday, reaching $49.23. The stock had a trading volume of 2,551,441 shares, compared to its average volume of 2,194,968. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The stock has a market capitalization of $124.94 billion, a PE ratio of 25.12, a P/E/G ratio of 1.23 and a beta of 0.57. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The stock has a 50-day simple moving average of $48.95 and a two-hundred day simple moving average of $52.11.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter in the previous year, the business posted $2.55 earnings per share. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. On average, equities analysts anticipate that Sanofi will post 4.06 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.